Title: The efficacy of CT-P13, a biosimilar of infliximab, in inflammatory bowel diseases: A
systematic review and meta-analysis
Version: 0 Date: 03 Jul 2024
Reviewer's report:
The efficacy of CT-P13, a biosimilar of infliximab, in inflammatory bowel diseases: A new
systematic review and meta-analysis
The authors conducted a systematic review and meta-analysis to assess the efficacy of the
infliximab biosimilar CT-P13 in patients with inflammatory bowel disease. While the study
addresses an interesting topic, it requires substantial revision.
Suggestions for Revision:
1) Remove the word “New” from the title.
2) In the introduction, it was stated that “at present, the principal treatment methods include
general anti-inflammatory therapy, hormonal anti-inflammatory therapy, immunosuppressants,
biological agents, fecal microbial transplantation, and surgical treatment”.
• Please clarify what is meant by hormonal anti-inflammatory therapy
• Fecal microbial transplantation is still considered experimental treatment for IBD
3) In the methods section, it is mentioned that the literature search included “PubMed, Embase,
Cochrane, Web of Science, and other databases”. Please specify which other databases were
searched.
4) The search was performed in June 2022. As this was over two years ago, it is recommended
to update the search to include more recent studies.
5) Please revise Forrest plots. They are currently confusing and, in some cases, incorrectly
labelled.
6) The results section is difficult to follow. Consider reporting only the overall OR for each
outcome and presenting the subgroup results (ie. 8-14 weeks, 24-30 weeks, 48-54 weeks,
7) Please describe the use of subgroups in the methods section.
8) Please provide more detail on how sensitivity analyses were conducted for age, sex,
concomitant medications, disease activity etc., as well as the results of these analyses.
9) Did all studies use the same dose and frequency of CT-P13? If not, explain how differences
were addressed.
10) Extensive editing is needed to improve the clarity of the manuscript.
Title: The efficacy of CT-P13, a biosimilar of infliximab, in inflammatory bowel diseases: A
systematic review and meta-analysis
Version: 0 Date: 03 Jul 2024
Reviewer's report:
The efficacy of CT-P13, a biosimilar of infliximab, in inflammatory bowel diseases: A new
systematic review and meta-analysis
The authors conducted a systematic review and meta-analysis to assess the efficacy of the
infliximab biosimilar CT-P13 in patients with inflammatory bowel disease. While the study
addresses an interesting topic, it requires substantial revision.
Suggestions for Revision:
1) Remove the word “New” from the title.
2) In the introduction, it was stated that “at present, the principal treatment methods include
general anti-inflammatory therapy, hormonal anti-inflammatory therapy, immunosuppressants,
biological agents, fecal microbial transplantation, and surgical treatment”.
• Please clarify what is meant by hormonal anti-inflammatory therapy
• Fecal microbial transplantation is still considered experimental treatment for IBD
3) In the methods section, it is mentioned that the literature search included “PubMed, Embase,
Cochrane, Web of Science, and other databases”. Please specify which other databases were
searched.
4) The search was performed in June 2022. As this was over two years ago, it is recommended
to update the search to include more recent studies.
5) Please revise Forrest plots. They are currently confusing and, in some cases, incorrectly
labelled.
6) The results section is difficult to follow. Consider reporting only the overall OR for each
outcome and presenting the subgroup results (ie. 8-14 weeks, 24-30 weeks, 48-54 weeks,
7) Please describe the use of subgroups in the methods section.
8) Please provide more detail on how sensitivity analyses were conducted for age, sex,
concomitant medications, disease activity etc., as well as the results of these analyses.
9) Did all studies use the same dose and frequency of CT-P13? If not, explain how differences
were addressed.
10) Extensive editing is needed to improve the clarity of the manuscript.
Please review this paper.
user
Title: The efficacy of CT-P13, a biosimilar of infliximab, in inflammatory bowel diseases: A
systematic review and meta-analysis
Version: 0 Date: 03 Jul 2024
Reviewer's report:
The efficacy of CT-P13, a biosimilar of infliximab, in inflammatory bowel diseases: A new
systematic review and meta-analysis
The authors conducted a systematic review and meta-analysis to assess the efficacy of the
infliximab biosimilar CT-P13 in patients with inflammatory bowel disease. While the study
addresses an interesting topic, it requires substantial revision.
Suggestions for Revision:
1) Remove the word “New” from the title.
2) In the introduction, it was stated that “at present, the principal treatment methods include
general anti-inflammatory therapy, hormonal anti-inflammatory therapy, immunosuppressants,
biological agents, fecal microbial transplantation, and surgical treatment”.
• Please clarify what is meant by hormonal anti-inflammatory therapy
• Fecal microbial transplantation is still considered experimental treatment for IBD
3) In the methods section, it is mentioned that the literature search included “PubMed, Embase,
Cochrane, Web of Science, and other databases”. Please specify which other databases were
searched.
4) The search was performed in June 2022. As this was over two years ago, it is recommended
to update the search to include more recent studies.
5) Please revise Forrest plots. They are currently confusing and, in some cases, incorrectly
labelled.
6) The results section is difficult to follow. Consider reporting only the overall OR for each
outcome and presenting the subgroup results (ie. 8-14 weeks, 24-30 weeks, 48-54 weeks,
7) Please describe the use of subgroups in the methods section.
8) Please provide more detail on how sensitivity analyses were conducted for age, sex,
concomitant medications, disease activity etc., as well as the results of these analyses.
9) Did all studies use the same dose and frequency of CT-P13? If not, explain how differences
were addressed.
10) Extensive editing is needed to improve the clarity of the manuscript.
assistant